Abstract
Objective: Different endovascular techniques are available for type II endoleak management. This scoping review aimed to summarize the available evidence on the use of N-Butyl cyanoacrylate (NBCA) for type II endoleak management. Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR). A protocol was registered on Open Science Framework. A systematic search using the PCC (Population, Concept, Context) framework was performed in PubMed, Scopus and Cochrane Library. Findings were systematically presented using structured tables summarizing NBCA techniques, efficacy and safety outcomes. Results: Following full-text assessment, 65 studies were included, comprising cohort and comparative studies, case reports, technical reports and preclinical studies. Single-arm cohort studies reported technical success rates of 90–100%, complication rates of 0–40% and variable durability outcomes, with clinical success ranging from 88 to 100%, endoleak resolution from 40 to 100% and aneurysm sac increase from 13 to 50%. Comparative studies reported improved outcomes with ethanol addition to the NBCA-ethiodized oil mixture compared with NBCA-ethiodized oil alone, shorter procedure times with direct puncture versus intra-arterial approach and more durable mid-term outcomes with selective embolization of contributing branches. Individually reported complications highlighted embolization risks and technical reports focused on catheter utilization. Pre-emptive embolization showed favorable outcomes on sac diameter reduction and endoleak type II occurrence. Conclusions: NBCA demonstrated technical feasibility for type II endoleak management, with variable durability. Considerable heterogeneity existed in access techniques, mixture ratios and outcome reporting. Preventive use demonstrated promising outcomes. Given the retrospective designs, limited sample sizes and heterogenous outcomes, adequately powered prospective studies are warranted.
Keywords: N-Butyl-cyanoacrylate, NBCA, embolization, type II endoleak, endovascular aortic repair
1. Introduction
Despite low morbidity and mortality rates, endovascular aortic repair remains associated with procedure-specific adverse events requiring long-term surveillance, such as device migration, kinking or endoleaks [1,2,3]. Type II endoleaks, resulting from retrograde blood flow into the aneurysm sac through collateral aortic side branches, such as the inferior mesenteric artery or segmental arteries, are the most frequently encountered endoleak subtype after aortic repair [4]. Almost 15% of electively treated patients exhibited a type II endoleak at completion angiography in large registry cohorts [5,6]. Although most of them resolve spontaneously and are considered of benign nature, persistent type II endoleak may lead to aneurysm sac enlargement, potentially compromising the durability of the proximal seal, increasing aneurysm pressurization and risk of rupture, as well as the need for reinterventions. Pre-emptive embolization of such side-branches has been proposed as an effective measure in well-selected patients, but its value remains controversial [4,7,8].
Various embolization techniques have emerged for the management of type II endoleak, including transarterial, translumbar, transcaval, or combined, selective or non-selective, approaches [9]. Embolic agents include solid materials, like coils and plugs, and liquid agents, such as thrombin, fibrin glue, ethylene-vinyl alcohol copolymer (ENOH) and N-butyl-cyanoacrylate (NBCA) mixtures [9]. NBCA has emerged as a compelling embolic alternative, either alone or in combination with adjunct materials, due to its favorable characteristics, including firm occlusion, coagulation independency, as well as adjustable viscosity and enhanced radiopacity, based on the ratios of its mixture with ethiodized oil [10]. Available evidence on the use of NBCA for type II endoleak embolization indicates high technical success with variable long-term clinical success [11,12]. Although the safety profile appears acceptable, significant adverse events have been described [13,14].
This scoping review aimed to systematically summarize the currently available literature on the use of NBCA for the management of type II endoleak in patients undergoing endovascular aortic repair, focusing on technical approaches, efficacy and safety outcomes.
2. Methods
2.1. Study Design and Eligibility Criteria
A scoping review of available literature was planned and performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) [15]. A pre-defined protocol was published in the Open Science Framework (OSF) registry (https://osf.io/98ejm; accessed on 7 July 2026). No approval by an ethics committee was required due to the study design.
Available literature, including observational studies (prospective and retrospective), interventional studies, case reports and technical notes that were published in English up to 25 June 2026 were eligible. Studies were eligible if they reported on patients undergoing endovascular aortic repair of any extent who received NBCA embolization either preemptively (during or before the index procedure to prevent type II endoleak) or therapeutically (after the index procedure for the treatment of an established type II endoleak). No restrictions were applied regarding the endograft design, the arteries related to type II endoleak, or the access approach. In vitro studies or studies performed on animal subjects were also included. Adjunctive use of other materials along with NBCA was considered acceptable.
Studies reporting on other types of endoleaks (e.g., Ia or gutter endoleaks) or the use of NBCA for interventions other than type II endoleak (preventive or therapeutic) management were excluded. Studies reporting mixed populations managed with different liquid embolic agents were excluded when NBCA-specific outcomes could not be extracted separately.
2.2. Information Sources and Search Strategy
A systematic literature search of English articles in PubMed, Cochrane Library and Scopus was conducted. This search was planned and performed based on the PCC (Population, Concept, Context) framework (Supplementary Table S1). The following terms, including Expanding Medical Subject Headings (MeSH Terms), were used: “endoleak”, “aneurysm sac perfusion”, “NBCA”, “n-butyl-cyanoacrylate”, “cyanoacrylate”, “Glubran”, “Histoacryl”, “Trufill”, and “glue” (Supplementary Table S2). The reference lists of individual eligible studies were screened for eligible articles, as a measure to account for the gray literature. The literature search was last updated on 25 June 2026, across all three online databases.
The retrieved literature was independently reviewed by two authors (G.A. and P.N.), in both stages of title and abstract screening, as well as full text assessment. Any disagreement was resolved after discussion with a third author (T.K.).
2.3. Data Collection
The data collection was performed using a standardized Excel file (Microsoft Corp., Redmond, WA, USA) that was created, and pilot tested by two authors (G.A. and P.N.). Collected data included, when available:
-
-
Study baseline characteristics (author, year, journal of publication, study design, study period, eligibility criteria, objective);
-
-
Baseline information regarding patients (sample size, age, sex, underlying disease, setting of repair, type of endovascular aortic repair, follow-up time, anticoagulation status, comorbidities);
-
-
Endoleak characteristics (feeding vessels, diagnostic imaging);
-
-
Technical details (type of approach, material details, NBCA mixture composition, use of adjuncts, outcome definitions);
-
-
Outcomes (reported clinical and technical outcomes, including effectiveness and complications, as available in the included studies).
The data collection process was performed independently by two authors (G.A. and P.N.). Any disagreements were resolved after thorough discussion with a third author (T.K.) until consensus was reached.
2.4. Quality Assessment
A formal critical appraisal of the methodological quality or risk of bias of the included studies was not performed. Although planned in the protocol if deemed appropriate, it was ultimately considered beyond the scope of this scoping review, given the descriptive nature of the available evidence, which included diverse study designs and heterogenous outcome reporting, further limiting the comparability of the evidence.
2.5. Synthesis and Presentation of the Results
A descriptive and narrative synthesis was performed. Findings were summarized according to study characteristics, technical approaches and reported outcomes. Due to substantial heterogeneity in study designs, patient populations, and reported outcomes, no quantitative synthesis was conducted.
Results were organized to map patterns of NBCA use, including technical strategies, efficacy outcomes and safety profiles in the existing literature. Respective summary tables were created. Numerical data were presented as counts and percentages for categorical variables and either mean ± standard deviation or median with range/interquartile range, when available or appropriate.
3. Results
3.1. Study Selection
The systematic search of the literature initially identified 387 study reports. After the deduplication process and eligibility evaluation, 65 studies were included in this scoping review (Figure 1).
Figure 1.

PRISMA flow diagram of the scoping review.
Among the included studies, four were non-human experimental studies, 16 were observational cohort studies, comprising 13 single-arm and three comparative studies, and 29 were case reports, including 13 reports describing the use of NBCA and 16 reports focusing on significant complications. Moreover, 11 studies were technical reports, analyzing various aspects, one study evaluated the cost-effectiveness of two NBCA alternatives and four studies focused on pre-emptive embolization outcomes. Across the included human studies comprised a cumulative sample size of 607 NBCA-treated patients was reported, although potential overlap between patient populations across different publications could not be excluded.
3.2. Non-Human Studies
NBCA was first experimentally used for type II endoleak management in swine models in 2000 by Schurink et al., who investigated the effect of NBCA on endoleak exclusion, aneurysm sac pressure and thrombosis [16]. On the experimental basis of a swine model, Rolland et al. have also shown that the pre-emptive injection of an NBCA mixture (NBCA with ethiodized oil at 1:4 ratio) into the aneurysm sac and feeding arteries can prevent endoleak formation and persistence after endovascular aortic repair while triggering a restenosis-related tissue reaction of the aortic aneurysm [17]. In 2018, another study on swine models used an NBCA–ethiodized oil–ethanol mixture (1:5:1 ratio) and showed successful endoleak type II management in all four cases immediately after the embolization, as well as aneurysm sac thrombosis, which persisted three months after the intervention [18]. According to the authors, the addition of ethanol to the mixture may enhance the safety due to its decreased adhesion to the catheter wall and less damage to the aortic tissue, preserving the efficacy of the technique [18].
An in vitro study by Barge et al., using a flowing model simulating an aneurysm sac with endoleak, was used to assess the catheter adhesion while administering NBCA through translumbar access [19]. Although no resistance was noted for metallic needles and straight catheters, curved catheters and sheaths adhered to the aneurysm sac [19].
3.3. Single-Arm Cohort Studies
Of 13 single-arm single-center cohort studies (including case series) that were eligible for this review, Charitable et al. presented the largest cohort among eligible studies, consisting of 30 patients treated via a translumbar approach for type II endoleak after EVAR [20]. Seven studies reported on mixed cohorts including either alternative endoleak types or alternative embolic agents; however, results on NBCA use for type II endoleaks were extractable [12,21,22,23,24,25,26]. Voigt et al., although including 32 cases, reported on prevalence of periaortic inflammation in this cohort (4/32) and focused on analyzing outcomes of these patients [26]. A transcaval approach was only reported in one study [27]. Seven studies analyzed outcomes of small series, including less than ten patients [22,23,24,25,28,29,30]. One study, including three NBCA-embolized patients, reported, additionally, on the cost-effectiveness of a watchful strategy, leading to reintervention for type II endoleak after six months and as long as an aneurysm sac increase is present [23]. Chao et al. systematically performed coil embolization of IMA before NBCA application to avoid embolization complications [30], while Nakai et al. aimed to assess the efficacy of Technetium- 99m SPECT in follow-up imaging assessment of embolized patients [25].
In total, 176 patients were treated via an intra-arterial (66 cases), translumbar (95 cases), transabdominal (seven cases) or transcaval access (10 cases). Although the outcomes of interest were heterogenous, technical success was evaluated in six studies and ranged between 90 and 100% [12,21,22,24,25,28], with endoleak resolution (seven studies) ranging between 40 and 100% [11,20,22,25,28,29,30]. Endoleak recurrence was evaluated in three studies and ranged between 0 and 30% [21,23,27]. The clinical success was evaluated in three studies and ranged between 88 and 100% [12,22,24], while reinterventions due to reoccurrence (four studies) ranged between 12 and 15% [11,20,28,30], and aneurysm sac increase (four studies), ranging between 13 and 50% [20,22,27,29].
Among these studies, any type of complication was reported in nine studies [11,20,22,23,24,26,27,28,29,30], and ranged between 0 and 40%, with six studies reporting a complication rate of 0% [20,23,24,28,29,30]. The type of complication was post-operative back pain in four patients [22,27], NBCA muscle infiltration leading to back pain and fever in two patients [11], and a case of a vena cava minor extravasation [27]; all reported complications were self-limiting. One study reported only on periaortic inflammation after NBCA application [26]. The NBCA mixture consisted of NBCA and ethiodized oil at variable ratios among studies, ranging between 1:1 and 1:10, and it was used along with coils in some cases. Median/mean follow-up ranged from 6 months to 83 months (Table 1).
Table 1.
Cohort studies (including case series) reporting on cases managed with NBCA embolization for type II endoleak.
| Author | Year | Sample | Access Route | NBCA Mixture | Main Findings | Follow-Up |
|---|---|---|---|---|---|---|
| Lagios et al. [11] | 2018 | 25 | TL-S | NE (23–50% NBCA) |
|
18.3 ± 7.3 months |
| Jiang et al. [21] * | 2025 | 25 | IA-S | NE (1:8–10) |
|
Not reported |
| Hamidizadeh et al. [12] * | 2021 | 20 | IA-S: 9, TL-nS: 11 |
NE (1:1–1:3) ± coils |
|
44.7 ± 33.5 months (whole cohort) |
| Charitable et al. [20] | 2019 | 30 | TL-nS | NE (1:2.5) ± coils |
|
19.1 (95% CI 11.1–27.2) months |
| Voigt et al. [26] * | 2026 | 32 | IA: 20 TL: 12 |
NE ± coils or ENOH |
|
Not reported |
| Van Sickler et al. [27] | 2023 | 10 | TC-nS: 10 | NE (1:2–10) |
|
6.5 (0–14.8) months |
| Kajiwara et al. [22] * | 2016 | 5 | IA: 4-S TA: 1-nS |
NE (1:2–10) + coils |
|
6± 6.2 months |
| Stavropoulos et al. [28] | 2005 | 9 | TL-nS | NE (1:2) |
|
83 (32–179) months |
| Steinmetz et al. [23] * | 2004 | 3 | TL-nS | NE (1:2–10) ± coils |
|
16 (6–26) months |
| Buckenham et al. [29] | 2008 | 4 | IA-S | NE (1:1) |
|
359 (173–365) days |
| Chao et al. [30] | 2006 | 4 | TL-nS (3) IA-nS (1) TA-nS (2) |
NE (1:3) + coils |
|
55.5 (30–78) months |
| Choi et al. [24] * | 2010 | 2 | TA-nS | NE (1:1–3) ±coils |
|
16.4 (0–37) months (whole cohort) |
| Nakai et al. [25] * | 2015 | 7 | IA-S (3) TL-nS (2) TA-nS (2) |
NE |
|
30.4 (12–48) months (whole cohort) |
Footnote: TL: translumbar; IA: intra-arterial; TC: transcaval; nS: non-selective; S: selective; NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil; ENOH: ethynele-vinyl alcohol copolymer. Follow-up was reported in mean ± standard deviation or median (range), if not otherwise stated. *: Study sample consisted of mixed populations, but data on patients treated with NBCA embolization for type II endoleak were extractable.
3.4. Comparative Studies
Three single-center studies provided extractable outcomes on management of type II endoleak using NBCA embolization (Table 2). The respective studies focused on comparing different mixture compositions [31] and access routes [32,33].
Table 2.
Comparative studies reporting on NBCA-treated patients for type II endoleak.
| Author | Year | Comparison Groups | Technical Aspects | Main Findings | Follow-Up |
|---|---|---|---|---|---|
| Fujitsuna et al. [31] | 2024 |
|
|
|
NE: 960 d (±1007) NEE: 484 d (±192) |
| Stavropoulos et al. [32] | 2009 |
|
|
|
18.7 m (6–84) |
| Ushijima et al. [33] | 2020 |
|
|
|
- |
Footnote: NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil; NEE: mixture containing n-butyl cyanoacrylate, ethiodized oil and ethanol; IA: intra-arterial; TL: translumbar; DP: direct puncture; TA: transabdominal; S: selective; nS: non-selective; vs.: versus; d: days; m: months; Follow-up time is expressed as mean (± standard deviation) or median (range).
Comparison between patients treated with an NBCA–ethiodized oil (NE) mixture versus an NBCA-ethiodized oil–ethanol (NEE) mixture, revealed significant superiority of the NEE in freedom from sac enlargement and freedom of reintervention at one year. No adverse events were reported, while the access route was either intra-arterial or through direct sac puncture (translumbar or transabdominal), differences between groups in a subgroup analysis for direct sac access-managed patients remained statistically significant [31].
In an early study from 2009, intra-arterial type II endoleak management using coils and translumbar management using coils and NE mixture were compared demonstrating no significant difference in terms of technical, clinical success and major complications. However, translumbar access was related to lower clinical success (72.6% vs. 78.3%) and two major complications, including bowel ischemia of embolic nature and retroperitoneal bleeding [32]. A later study comparing direct sac puncture embolization with NE to intra-arterial embolization with NE, with or without adjunctive coil deployment, showed similar technical success but a significant difference in procedure time and contrast use, favoring direct sac puncture [33].
3.5. Case Reports
Multiple case reports have reported on patients managed with NBCA for type II endoleaks (Table 3). The first (chronological) report demonstrates the adjunctive role of NBCA mixture in the successful management of a recurrent type II endoleak after endovascular abdominal aortic aneurysm repair (EVAR) [34]. Subsequent reports confirm further the efficacy of this method in emergent setting, where either ruptured abdominal aortic aneurysms (AAAs) or aortocaval fistulae were treated [35,36,37,38]. Cases of co-existent multiple endoleaks are also reported, including one report of transgraft embolization with subsequent endograft relining [35,36,39].
NBCA embolization was also applied after arch repair with FET, due to an LSA-related type II endoleak, while type II endoleaks after iliac aneurysm repair were also reported [40,41,42]. Special access routes, including transgluteal or complex intra-arterial access (due to previous hybrid repair) have been documented [42,43]. Uncommon imaging modalities, including carbon-dioxide angiography, photon emission computer tomography and non-contrast magnetic resonance tomography, were used to assist intraoperative technical success or post-operative follow-up [44,45,46]. The existence of an extended vascular network in the aortic wall (vasa vasorum), feeding the endoleak nidus, was, repeatedly, noted [40,41,44].
Table 3.
Case reports presenting cases managed with NBCA for type II endoleak.
| Author | Year | Clinical Context | Access Route | NBCA Mixture | Follow-Up | Special Features |
|---|---|---|---|---|---|---|
| Wilmot et al. [34] | 2007 | Recurrent type II EL after EVAR | TL-nS | NE (1:2) | - | Previous IMA endoleak treated with coils, concurrent LA endoleak treated with coils |
| Fukunishi et al. [44] | 2026 | Vasa vasorum (Moyamoya) type II EL after EVAR | IA-S | NE (1:4) | 1 year | CO2 angiography to reduce antegrade flow and avoid embolization distally |
| Hamada et al. [41] | 2019 | Type II EL from reticular artery after EVAR for CIAA | IA-S | NE (1:5) | 9 months | Endoleak from reticular artery arising from DCIA and being anastomosed to a network of reticular arteries in the aortic wall |
| Claudio et al. [42] | 2023 | Type II EL from iliolumbar artery after exclusion of an IIAA | TG-nS | - | 1 month | Endoleak despite Onyx sac embolization, initial transarterial attempt failed, transgluteal succeeded |
| Chiba et al. [40] | 2026 | Type II EL from atypical mediastinal collateral artery | IA-S | NE (14.5% NBCA) | 1 year | Previous FET with extra-anatomic LSA bypass, endoleak from atypical mediastinal branch connected to a network of vasa vasorum |
| Onishi et al. [43] | 2023 | Type II EL from CT after hybrid repair of TAA | IA-S | NE (1:5) | 8 days | Branches of CT initially coil embolized- endoleak from dorsal pancreatic artery- selectively embolized through bypass graft and SMA |
| Nakai et al. [39] | 2019 | Mixed endoleak (I, II and III) after EVAR | TGr-nS | NE (1:4) | 6 months | Transgraft embolization, concurrent proximal and distal extension, kissing endograft, main endograft relining |
| Kuziez et al. [35] | 2018 | Ruptured AAA due to mixed EL (type II from LAs and Ia) after EVAR | TL-nS | NE (1:2.5) | 18 months | Emergent setting, concurrent proximal extension with snorkel for LRA |
| Laganà et al. [36] | 2008 | Ruptured AAA due to mixed EL (type II from iliolumbar and IIIa) after EVAR | IA-S | NBCA | 6 months | Emergent setting, concurrent type IIIa endoleak from left limb disconnection |
| Maleux et al. [37] | 2025 | Ruptured AAA due to type II EL from LAs after EVAR | TL-nS | NE (1:3) | 1 year | Emergent setting |
| Burke et al. [38] | 2003 | Aortocaval fistula supplied by type II EL from IMA | IA-S | NE (1:3) | 1 year | Aortocaval fistula, emergent setting |
| Pietura et al. [45] | 2022 | Type II EL from iliolumbar arteries after EVAR | IA-S | NE (16% NBCA) | Residual endoleak post-op | NCE-MRI for the assessment of result |
| Nakai et al. [46] | 2014 | Type II EL after EVAR | TA-nS | NE (1:2) + coils | 12 months | Use of Technetium-99m HSAD-SPECT |
Footnote: EL: endoleak; EVAR: endovascular aortic repair; LA: lumbar artery; CT: celiac trunk; IMA: inferior mesenteric artery; CIAA: common iliac artery aneurysm; IIAA: internal iliac artery aneurysm; TL: translumbar; IA: intra-arterial; TG: transgluteal; TGr: transgraft; nS: non-selective; S: selective; NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil; CO2: carbon dioxide; FET: frozen elephant trunk; LSA: left subclavian artery; NCE-MRI: non-contrast enhanced magnetic resonance imaging; DCIA: deep circumflex iliac artery; HSAD-SPECT: human serum albumin diethylenetriamine pentaacetic acid single-photon emission computer tomography.
3.6. Technical Studies
Eleven technical studies were included, focusing mainly on catheter systems (Table 4). Forty-one cases were analyzed, with the intra-arterial approach being the most commonly use (7/11 studies). Five studies aimed to present multi-coaxial systems of catheters and microcatheters, used to achieve effective embolization via an intra-arterial access [47,48,49,50,51], while one study described the applied coaxial catheter system for a direct-puncture technique [52]. The use of flow-directed microcatheters has been supported as an effective alternative [53]. Balloon occlusion of the aorta during the embolization process was, also, described as a means to enhance efficacy and safety of embolization [51,54]. Moreover, the use of a transeptal needle-sheath to establish a transcaval access and the use of isocenter marking and contrast-enhanced ultrasonography for the application of transpendicular and transabdominal access have been described [55,56,57]. Different mixture ratios were used, ranging from 1:2 to 1:5; The respective information and clinical outcomes, are presented in Table 4.
Table 4.
Technical studies reporting on patients with type II endoleak managed with NBCA embolization.
| Author | Year | Clinical Context | Access Route | NBCA Mixture | Follow-Up | Main Findings—Recommendations |
|---|---|---|---|---|---|---|
| Shimohira et al. [47] * | 2013 | Type II endoleak after EVAR (1 case) | IA-S (1) | NE (17% NBCA) | 4 months | Triaxial catheter system
|
| Saguchi et al. [48] | 2024 | Type II endoleak after EVAR (3 cases) | IA-S | NE (20% NBCA) | - | Quintet-coaxial catheter system
|
| Okada et al. [49] | 2024 | Type II endoleak after EVAR (1 case) | IA-S | NE (1:4) | 5 months | Triple coaxial microcatheter system through deep iliac circumflex artery
|
| Hongo et al. [50] | 2014 | Type II endoleak after EVAR (20 cases) | IA-nS | NE (20–30% NBCA) | 18.5 (6–36) months | Double coaxial microcatheter system
|
| Mine et al. [51] * | 2020 | Type II endoleak after EVAR (2 cases) | IA-S | NE (1:3) | 4.5 (1–10) months | Triaxial microcatheter system for transarterial warmed NBCA embolization under balloon occlusion
|
| Katada et al. [52] | 2013 | Type II endoleak after TEVAR/EVAR (2 cases) | DP-nS | NE (1:1–2) | 4.5 (3–6) months | Coaxial DP technique
|
| Kamada et al. [53] | 2025 | Persistent type II endoleak after TEVAR (3 cases) | IA-S (2) IA-nS (1) | NE (1:2) | 4 (1–6) | Use of flow-directed microcatheters
|
| Ogawa et al. [54] | 2019 | Type II endoleak after EVAR (6 cases) | IA-nS (1) IA-S (3) DP-S (1) DP-nS (1) |
NE (1:2–3) | 10 months | Balloon aortic occlusion
|
| Midulla et al. [55] | 2012 | Persistent type II endoleak after EVAR (1 case) | TC-nS | NE | - | Transcaval embolization using transseptal needle-sheath
|
| Ogawa et al. [56] | 2015 | Type II endoleak after EVAR (1 case) | TP-nS | NE (1:3) | 8 months | Isocenter puncture DP technique
|
| Churchill et al. [57] | 2021 | Type II endoleak after EVAR (1 case) | TA-nS | NE (1:3) | 2 months | Contrast-enhanced ultrasonography
|
Footnote: IA: intra-arterial; DP: direct puncture; TC: transcaval; TP: transpendicular; TA: transabdominal; NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil. Follow-up is reported in mean ± standard deviation or median (range). Follow-up was reported in mean ± standard deviation or median (range). *: Study sample consisted of mixed populations, but data on patients treated with NBCA embolization for type II endoleak were extractable.
3.7. Complications
Case reports have been published focusing on clinically significant or unusual complications resulting from interventions aiming to manage type II endoleaks with the use of NBCA (Table 5). Nine of them include complications of embolic cause [14,58,59,60,61,62,63,64,65]. Colonic ischemia with subsequent need for colectomy or conservatively managed ischemic colitis have been reported after IMA embolization [60,63,64], while management of endoleaks involving lumbar arteries has led to neurological adverse events of variable severity involving lower limb motor function, with only one out of four demonstrating complete resolution [14,58,59,61]. NBCA lumbar artery embolization has also been reported to cause skin ulcerations, resulting due to muscle infiltration of the embolic substance [65]. Distal glue embolization has been recorded, with subsequent need for peripheral lower limb revascularization [62].
Table 5.
Case reports presenting complications after NBCA embolization for the management of type II endoleak after EVAR.
| Author | Year | Technical Approach | Mixture | Complication | Management |
|---|---|---|---|---|---|
| Embolic | |||||
| Forester et al. [58] | 2002 | Intra-arterial, selective | NBCA– tantalum powder | Ischemic sciatic neuropathy, right sided foot drop | Conservative management, limited recovery |
| Sanz- Sánchez et al. [59] | 2019 | Intra-arterial, selective | NE (1:5 ratio) | Spinal cord ischemia leading to paraplegia | Methylprednisone injection and CSF drainage (only minimal improvement with minimal hip and knee flexion) |
| Gabel et al. [60] | 2018 | Translumbar, non-selective | NBCA (no info) | Ischemic colitis (sigmoid colon) | Sigmoidectomy |
| Saiga et al. [61] | 2022 | Intra-arterial, selective and non-selective | NE (5% NBCA for selective +10% for non) | Ischemic lumbar plexopathy, sensory/motor impairment of anteromedial inner thigh | Rehabilitation (persisted, not solved) |
| Chun et al. [14] | 2020 | Intra-arterial, non-selective | NE (1:4 ratio) | Spinal cord ischemia and ischemic radiculopathy (pain) | No management, gradual symptom elimination |
| Metias et al. [62] | 2015 | Translumbar, non-selective | NE (1:4 ratio) | Acute limb ischemia due to distal glue embolization | Arteriotomy and selective embolectomies |
| Lanza et al. [63] | 2014 | Intra-arterial, selective | NE (1:2) | Colonic ischemia, peritoneal fistula | Total colectomy, iliorectal anastomosis, protective ileostomy |
| Ito et al. [64] | 2012 | Intra-arterial, selective | NE (1:4) | Ischemic colitis | Conservative management |
| Bailey et al. [65] | 2011 | Intra-arterial, non-selective | NE (3.5:1) | Ischemic skin ulceration | Conservative, self-limiting |
| Other | |||||
| Ueda et al. [66] | 2026 | Translumbar, non-selective | NEE (1:4:1) | Acute bilateral lower limb ischemia from compression | Kissing stents, thromboaspiration |
| Maleux et al. [67] | 2026 | Translumbar, non-selective | NE (1:2) | Limp graft occlusion due to external compression | No treatment (asymptomatic) |
| Ni et al. [68] | 2018 | Translumbar, non-selective | NE (10% NBCA) | Ovation stent graft extrinsic compression of the unsupported part | Kissing balloon angioplasty (stenosis resolved) |
| Al Adas et al. [13] | 2018 | Translumbar, non-selective (transarterial selective failed) | NE (1:5 ratio) | Hemodynamically significant compression of the right iliac graft limb (intra-OP) | Balloon angioplasty (stenosis resolved) |
| Robinson et al. [69] | 2024 | Transcaval, non-selective | NBCA (no info) + coils | Graft infection | Endograft explantation and implantation of cryopreserved allograft |
| Balézeaux et al. [70] | 2024 | Translumbar, non-selective | NE (1:4) | Aortic infection | Retroperitoneal exploration, aortoiliac bypass. |
| Li et al. [71] | 2019 | Transabdominal, non-selective | NE (no ratio reported) | Graft infection | Endograft explantation and neoaortic reconstruction |
Footnote: NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil; NEE: mixture containing n-butyl cyanoacrylate, ethiodized oil and ethanol; CSF: Cerebrospinal Fluid.
Acute limb ischemia due to iliac limb external compression caused by the embolic agent in four cases [13,66,67,68]. Three of them were treated acutely due to symptomatic state with kissing balloon angioplasty [13,66,68], while one asymptomatic patient was conservatively managed [67]. Aortic graft and/or aortic infection has also complicated such interventions, leading in all cases to extensive open aortic reconstructions [65,69,70,71].
3.8. Cost-Effectiveness
A cost-effectiveness study comparing two alternative commercial preparations, Trufill and Histoacryl, was published in 2021. After comparing 20 Trufill to 14 Histoacryl, managed in a single tertiary center in the USA, between March 2011 and September 2018, for type II endoleak cases, managed via translumbar approach, results have shown that the procedure cost was significantly higher for Trufill, with more coils and less glue used in this group. Percentage change in sac diameter did not differ between groups and no complication was reported [72].
3.9. Pre-Emptive Embolization
Pre-emptive embolization using NBCA was reported by four single-center studies. Selective and non-selective pre-emptive embolization of aortic side branches (lumbar arteries and inferior mesenteric arteries) with NBCA, as a measure to prevent type II endoleak during endovascular aortic repair of AAA demonstrated a 3.2% of aneurysm sac diameter reduction and 17% persistent endoleak type II after 6 months [73]. Nakai et al. applied non-selective pre-emptive embolization using NEE mixture in 24 patients with endovascular repair of AAA, with either infrarenal neck angulation of >60° or AAA diameter of >60 mm, and reported low systolic sac pressure indexes (systolic pressure in aneurysm sac/systematic systolic pressure), no aneurysm diameter increase and a 12.5% persistent endoleak type II rate at 12 months [74].
A comparative study between patients treated with EVAR alone versus EVAR combined with non-selective NE pre-emptive embolization demonstrated significant superiority for the embolization group regarding type II endoleak occurrence at 7 days and AAA diameter reduction at 12 months [75]. An updated version of this study confirmed these findings and reported a significant difference in survival without AAA enlargement and survival without reintervention, favoring the embolization group (Table 6) [76].
Table 6.
Studies reporting on pre-emptive embolization with NBCA for the preventive management of endoleaks type II.
| Author | Year | Study Period | Patients | Mixture | Important Reported Outcomes | Follow-Up |
|---|---|---|---|---|---|---|
| Okada et al. [73] | 2024 | 2018–2019 | 12 |
|
|
6 months |
| Nakai et al. [74] | 2016 | 2013–2015 | 24 | NEE: 1:5:0.5 (non-selective) |
|
12.1 months ± 5.8 |
| Miura et al. [75] | 2020 | 2013–2018 |
|
NE: 1:6 to 1:9 (non-selective) |
|
12 months |
| Miura et al. [76] | 2024 | 2013–2020 |
|
NE: 1:6 to 1:9 (non-selective) |
|
12 months |
Footnote: NBCA: n-butyl cyanoacrylate; NE: mixture containing n-butyl cyanoacrylate and ethiodized oil; NEE: mixture containing n-butyl cyanoacrylate, ethiodized oil and ethanol; AAA: abdominal aortic aneurysm; TII: type II (endoleak); SPI: systolic pressure index; follow-up time is expressed as absolute number or mean ± standard deviation.
Beyond its therapeutic application for established type II endoleaks, NBCA embolization has also been investigated in a limited number of studies as a pre-emptive strategy during EVAR. Although these approaches represent distinct clinical strategies, both ultimately aim to enhance the durability of endovascular aortic repair by eliminating sources of persistent aneurysm sac perfusion, thereby reducing the risk of subsequent sac enlargement and related complications.
4. Discussion
This scoping review systematically mapped the available evidence regarding the use of NBCA for the management of type II endoleak in patients receiving endovascular aortic repair. Non-human studies proved feasibility of both therapeutic and preventive application of the technique [16,17,18,19]. Available cohort studies including multiple alternative approaches and NBCA mixture ratios, indicated high rates of technical success and variable rates of clinical success, assessed through endoleak resolution and recurrence, aneurysm sac size changes and reinterventions [11,12,20,21,22,23,24,25,26,27,28,29,30,31,32,33]. Reported complications were uncommon, mainly reported in case reports, and comprising both embolic and non-embolic complications, such as endograft infection and compression; potential underreporting should be considered, further compounded by the limited availability of long-term follow-up data [13,14,58,59,60,61,62,63,64,65,66,67,68,69,70,71]. Technical reports assessed the performance of multiple alternative catheter systems and access approaches, demonstrating acceptable results [47,48,49,50,51,52,53,54,55,56,57]. Use of NBCA for the prevention of type II endoleak is also feasible with available studies reporting high outcome durability and low complication rates [73,74,75,76].
Available guidelines suggested endoleak type II management, based on aneurysm sac growth criteria, but no specific method or technique was proposed [2]. Compared to previous cumulative evidence on type II endoleak management with various embolic agents, suggesting highly variable technical success and modest clinical success rates, the included studies suggested generally favorable technical success with NBCA embolization, while conclusions regarding its long-term effectiveness and durability remained limited by the heterogenous methodological characteristics of the available studies [9,77]. Aneurysm sac increase rates and reintervention rates were in agreement with previous cumulative evidence [77,78]. With regard to pre-emptive embolization with NBCA or other material, the available evidence was still controversial regarding the benefits of such an approach, with selected cases benefiting from lower endoleak type II occurrence, reintervention and sac increase [75,76,79]. The importance of durable type II endoleak management is further highlighted by the potential consequences of persistent sac perfusion. Although type II endoleaks are not identified as the primary cause of EVAR failure and aneurysm rupture, persistent sac perfusion may contribute to aneurysm sac enlargement and subsequent aortic morphological changes, potentially compromising the proximal sealing zone and promoting secondary type I (or even III endoleaks). Such complications may increase the risk of rupture and necessitate complex reinterventions, including endograft explantation, which are associated with substantial morbidity and mortality. However, the impact of specific embolization strategies, including NBCA, on preventing such outcomes remains unclear [80,81].
NBCA mixtures are mainly built from NBCA plus an oil-based contrasted agent, ethiodized oil (Lipiodol; Guerbet, Villepinte, France). This additional agent is mixed with NBCA in variable ratios and acts like a radiopaque carrier and diluter, modifying its polymerization time [82]. High ethiodized oil content is preferred for non-selective embolization, while mixtures containing less ethiodized oil are chosen for selective embolization, to induce faster polymerization and avoid distal embolism of the mixture [73]. Although this constitutes the general rule, it is not always strictly followed and ratios are not standardized but are rather operator-dependent, as is confirmed in this review [83]. Several commercially available NBCA-based formulations exist, including Histoacryl (B. Braun, Melsungen, Germany), Glubran 2 (GEM S.r.l., Viareggio, Italy) and Trufill (Cerenovus, Irvine, CA, USA), which differ in composition, additives and polymerization characteristics. Although these preparations have been used for embolization procedures, comparative evidence regarding their use in type II endoleak management remains limited, and current practice appears mainly driven by operator preference, availability and local regulations [72,84].
The addition of ethanol to the mixture was proposed, indicating its positive effect on better handling of the mixture, lower risk of adhesion to the catheter and a better profile of vascular wall changes [85]. Available evidence on type II management, supports the superior outcomes of the mixture [31]. Mixture temperature also plays a role in its viscosity with evidence supporting higher temperature leading to reduced viscosity [86]. The addition of coils to the strategy was also described multiple times, but no available evidence reported any difference between these alternatives while the application of coils for selective embolization of specific feeding vessels to securely prevent NBCA mixture embolization seems reasonable [30]. Conversely, the use of liquid embolic agents may be particularly advantageous in cases involving complex networks of type II endoleak feeding vessels (vasa vasorum), with individual reports supporting the feasibility of NBCA embolization in these settings [40,44].
The access route for the application of this embolization with NBCA also showed great heterogeneity across the included studies. Intra-arterial and translumbar accesses were the most commonly used, providing similar efficacy and safety outcomes, with translumbar puncture being superior in terms of procedural time and contrast volume [32,33]. The transabdominal approach was also described under appropriate imaging guidance [33,57]. Transcaval embolization also constituted a concrete alternative presenting excellent technical success and almost 90% of clinical success and freedom from type II endoleak recurrence [78]. Alternative unusual access routes, like transgluteal, transpedicular or transgraft were used, proving the customizability of the technique, but reducing the standardization of the methodology [39,42,56]. Both selective and non-selective embolization can be applied, with low-powered comparative evidence showing significantly higher clinical success for the selective one [87].
Available studies reported comparable or potentially favorable outcomes with NBCA relative to previously reported evidence on other embolic materials, although the strength of these findings remains limited by the methodological characteristics of available evidence. In a cohort where multiple embolic agents were applied, including NBCA in combination with coils, coil embolization alone was associated with a higher rate of reinterventions while another cohort study demonstrated significantly higher technical success with NBCA compared to other liquid embolic agents and coils [12,88]. Sac enlargement was not shown to be affected by the choice of coil alone or NBCA, with or without coils [89]. Similarly to NBCA, the alternative liquid embolic agent ethylene-vinyl-alcohol copolymer (Onyx; Medtronic, Irvine, CA, USA) demonstrated high technical success and variable clinical success [90,91]. Fibrin glue also showed enhanced effectiveness and durability, particularly in the setting of preventive embolization, as supported by high quality studies [92,93].
Despite generally favorable outcomes reported in cohort studies, NBCA mixture properties and the lack of adequate technique standardization bear an inherent risk of embolic complications [11,20]. The adhesive properties of the mixture may complicate the procedure, with adhesion of the agent to the catheter and may lead to endovascular foreign body entrapment [19]. Additionally, the initial fluidity of the embolic agent can lead to unplanned polymerization in an undesired vascular territory, including the aneurysmal sac and iliac arteries, and subsequent endograft compression [66]. Aortic graft infection is a rare complication and may be related to the need for multiple reinterventions, although robust evidence is lacking [94]. The interpretation of complication rates remains limited due to the heterogenous reporting, small study populations, and inconsistent follow-up across the available literature.
Currently available evidence includes several studies reporting mixed populations in terms of endoleak type and embolic agent, limiting the extraction of NBCA-specific outcomes and robust conclusions regarding its performance. Comparative studies involving predominantly NBCA-managed patients evaluated selective versus non-selective embolization and direct puncture versus intra-arterial approaches, reporting shorter intraoperative times and reduced fluoroscopy with non-selective technique and direct puncture [95,96]. Cohort studies reported favorable efficacy and safety outcomes with both intra-arterial and transabdominal approach, while one study assessing long-term durability of the NBCA embolization outcomes highlighted the low five-year freedom of aneurysm sac increase [88,97,98].
5. Limitations
The available evidence is predominantly based on retrospective, underpowered cohort studies and case reports, limiting the overall strength of conclusions. Substantial heterogeneity exists across studies regarding access approaches, embolization techniques, feeding vessel selectivity, NBCA mixture ratios and use of adjunctive embolic materials. Added to this, confounding by indication is inherent in the included single-center, non-randomized, retrospective studies with the above-mentioned heterogenous characteristics, as treatment selection may have been influenced by anatomical characteristics, operator preferences and institutional practices, limiting causal interpretation of the reported differences, including those reaching statistical significance (p < 0.05). Follow-up duration and outcome reporting were also inconsistent, reducing the comparability between studies. The reported outcomes, particularly complications, may be influenced by reporting bias. Heterogeneity in commercially available NBCA formulations may represent an additional confounder, potentially affecting technical performance and reported outcomes. Comparative analyses’ availability was scarce. Furthermore, overlap of patient populations across studies from the same institutions is highly likely, although its extent could not be determined. Consequently, the cumulative sample size may not represent the number of individual included patients.
Although formal quality assessment was not performed, consistent with the descriptive objectives of this scoping review, the absence of such an assessment limits the strength of conclusions regarding the efficacy and safety of NBCA embolization. Additionally, the restriction to English-language publications may have resulted in the omission of relevant evidence, particularly considering the substantial contribution of research centers from non-English speaking countries to the available literature. Future adequately powered, prospective studies, with systematic outcome assessment, addressing specific technical aspects like feeding vessel selectivity, access routes and NBCA mixture composition are necessary to enhance the quality of the available evidence and assist the standardization of NBCA embolization application.
6. Conclusions
Available evidence suggests that NBCA embolization for type II endoleak management is technically feasible, with generally favorable reported safety but variable durability. Considerable heterogeneity exists between the available studies, in terms of access approach, NBCA mixture ratios, adjunctive use of other embolic materials and reported outcomes.
A limited number of studies reporting on pre-emptive embolization using NBCA has shown promising short-term endoleak type II occurrence and aneurysm sac increase with an acceptable safety profile. The heterogenous and underpowered existing literature for both management and prevention of type II endoleak using NBCA prompts future studies of higher quality.
Supplementary Materials
The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jcm15218596/s1, Table S1: The PCC framework of the scoping review; Table S2: Search strategy of the scoping review.
Author Contributions
Conceptualization, T.K. and G.A.; methodology, G.A., G.P., D.Y.a.S. and C.-A.B.; data collection, G.A., P.N., J.I.T. and N.Z.; writing—original draft preparation, G.A. and P.N.; writing—review and editing, G.A., P.N., G.P., J.I.T., D.Y.a.S., N.Z., C.-A.B. and T.K.; supervision, T.K. All authors have read and agreed to the published version of the manuscript.
Institutional Review Board Statement
Ethical review and approval were waived for this study due to study design.
Informed Consent Statement
Patient consent was waived due to study design.
Data Availability Statement
Data are available upon request.
Conflicts of Interest
Tilo Kölbel is a consultant for Cook Medical and Getinge, and proctor for and has intellectual property with Cook Medical, receiving royalties, speaking fees, and research, travel, and educational grants. Petroula Nana is a consultant for Getinge receiving research and educational grants. All authors declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This research received no external funding.
Footnotes
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
References
- 1.Zaiem F., Almasri J., Tello M., Prokop L.J., Chaikof E.L., Murad M.H. A Systematic Review of Surveillance after Endovascular Aortic Repair. J. Vasc. Surg. 2018;67:320–331.e37. doi: 10.1016/j.jvs.2017.04.058. [DOI] [PubMed] [Google Scholar]
- 2.Wanhainen A., Van Herzeele I., Bastos Goncalves F., Bellmunt Montoya S., Berard X., Boyle J.R., D’Oria M., Prendes C.F., Karkos C.D., Kazimierczak A., et al. Editor’s Choice—European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur. J. Vasc. Endovasc. Surg. 2024;67:192–331. doi: 10.1016/j.ejvs.2023.11.002. [DOI] [PubMed] [Google Scholar]
- 3.Isselbacher E.M., Preventza O., Hamilton Black J., Augoustides J.G., Beck A.W., Bolen M.A., Braverman A.C., Bray B.E., Brown-Zimmerman M.M., Chen E.P., et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022;146:24. doi: 10.1161/cir.0000000000001106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Cifuentes S., Mendes B.C., Tabiei A., Scali S.T., Oderich G.S., DeMartino R.R. Management of Endoleaks After Elective Infrarenal Aortic Endovascular Aneurysm Repair. JAMA Surg. 2023;158:965. doi: 10.1001/jamasurg.2023.2934. [DOI] [PubMed] [Google Scholar]
- 5.Besch A., Heckenkamp J., Adili F., Steinbauer M., Cotta L., Behrendt C.-A. Editor’s Choice—Endovascular Treatment of Abdominal Aortic Aneurysm and Impact of Annual Caseload in the Quality Registry of the German Society for Vascular Surgery and Vascular Medicine (DGG) Eur. J. Vasc. Endovasc. Surg. 2025;70:567–574. doi: 10.1016/j.ejvs.2025.05.012. [DOI] [PubMed] [Google Scholar]
- 6.Pouncey A.L., Lübcke J., Peters F., Cotta L., Adili F., Behrendt C.-A. Evidence for Female Patient Disadvantage after Endovascular Aortic Repair in the Quality Registry of the German Society for Vascular Surgery and Vascular Medicine (DGG) Eur. J. Vasc. Endovasc. Surg. 2026. in press . [DOI] [PubMed]
- 7.Kim H., Lee S., Hwang D., Huh S., Yun W.-S., Kim H.-K. Prognostic Impact of Early Type II Endoleak Detected 1 Month after Endovascular Aneurysm Repair on Midterm Outcomes in a Two-Center Cohort. J. Vasc. Surg. 2026;83:1359–1368.e2. doi: 10.1016/j.jvs.2026.01.019. [DOI] [PubMed] [Google Scholar]
- 8.Nagel J.R., Driessen W., Groot Jebbink E., Versluis M., Reijnen M.M.P.J. Active Sac Management for Prevention of Type II Endoleaks after Endovascular Aneurysm Repair. Vasa. 2026;55:88–105. doi: 10.1024/0301-1526/a001237. [DOI] [PubMed] [Google Scholar]
- 9.Akmal M.M., Pabittei D.R., Prapassaro T., Suhartono R., Moll F.L., van Herwaarden J.A. A Systematic Review of the Current Status of Interventions for Type II Endoleak after EVAR for Abdominal Aortic Aneurysms. Int. J. Surg. 2021;95:106138. doi: 10.1016/j.ijsu.2021.106138. [DOI] [PubMed] [Google Scholar]
- 10.Kim H.-C., Miyayama S., Choi J.W., Kim D.H., Lee M., Hur S., Jae H.J., Chung J.W. Embolization with N-Butyl Cyanoacrylate: Properties, Techniques, Applications, and Pitfalls. Radiographics. 2026;46:5. doi: 10.1148/rg.250122. [DOI] [PubMed] [Google Scholar]
- 11.Lagios K., Karaolanis G., Bazinas T., Perdikides T., Bountouris I. Translumbar Infusion of N-Butyl Cyanoacrylate for the Treatment of Type II Endoleaks. J. Vasc. Interv. Radiol. 2018;29:826–832. doi: 10.1016/j.jvir.2018.01.788. [DOI] [PubMed] [Google Scholar]
- 12.Hamidizadeh R., Nzekwu E., Halliwell O. Factors Influencing Clinical Success Following Endovascular Treatment of Type II Endoleaks. Can. Assoc. Radiol. J. 2021;72:890–897. doi: 10.1177/0846537120981100. [DOI] [PubMed] [Google Scholar]
- 13.Al Adas Z., McVinnie D.W., Weaver M.R., Shepard A.D. Compression of Endograft Limb after Translumbar Embolization of a Type II Endoleak Using N-Butyl Cyanoacrylate. J. Vasc. Surg. Cas. Innov. Tech. 2018;4:327–330. doi: 10.1016/j.jvscit.2018.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Chun J.-Y., Morgan R. Ischaemic Sequelae Following Glue Embolization of Type 2 Endoleak Involving Multiple Lumbar Arteries. Cardiovasc. Interv. Radiol. 2020;43:1406–1408. doi: 10.1007/s00270-020-02581-8. [DOI] [PubMed] [Google Scholar]
- 15.Tricco A.C., Lillie E., Zarin W., O’Brien K.K., Colquhoun H., Levac D., Moher D., Peters M.D.J., Horsley T., Weeks L., et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann. Intern. Med. 2018;169:467–473. doi: 10.7326/m18-0850. [DOI] [PubMed] [Google Scholar]
- 16.Schurink G.W.H., Aarts N.J.M., van Baalen J.M., Kool L.J.S., van Bockel J.H. Experimental Study of the Influence of Endoleak Size on Pressure in the Aneurysm Sac and the Consequences of Thrombosis. J. Brit. Surg. 2000;87:71–78. doi: 10.1046/j.1365-2168.2000.01319.x. [DOI] [PubMed] [Google Scholar]
- 17.Rolland P.H., Vidal V., Mekkaoui C., Bertrand M.-F., Levrier O., Bartoli J.-M. Embolization-Driven Occlusion of the Abdominal Aortic Aneurysmal Sac as the Basis of Prevention of Endoleaks in a New Swine Model. Eur. J. Vasc. Endovasc. Surg. 2006;31:28–35. doi: 10.1016/j.ejvs.2005.07.018. [DOI] [PubMed] [Google Scholar]
- 18.Nakai M., Ikoma A., Loffroy R., Midulla M., Kamisako A., Higashino N., Fukuda K., Sonomura T. Type II Endoleak Model Creation and Intraoperative Aneurysmal Sac Embolization with N-Butyl Cyanoacrylate-Lipiodol-Ethanol Mixture (NLE) in Swine. Quant. Imaging Med. Surg. 2018;8:894–901. doi: 10.21037/qims.2018.10.01. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Barge J., Lopera J., Harper R., Cura M., Kroma G., El Merhi F., Suri R. In-Vitro Model of Translumbar Embolization of Endoleaks with NBCA: Risk of Gluing Different Access Devices. Vasc. Dis. Manag. 2009;6:92–98. [Google Scholar]
- 20.Charitable J.F., Patalano P.I., Garg K., Maldonado T.S., Jacobowitz G.R., Rockman C.B., Veith F.J., Cayne N.S. Outcomes of Translumbar Embolization of Type II Endoleaks Following Endovascular Abdominal Aortic Aneurysm Repair. J. Vasc. Surg. 2021;74:1867–1873. doi: 10.1016/j.jvs.2021.06.030. [DOI] [PubMed] [Google Scholar]
- 21.Jiang L.-P., Wang Q.-B., Wang X., Zhang H.-M., Ren L.-Y. Clinical Application of N-Butyl-2- Cyanoacrylate (NBCA) in the Transarterial Embolization for Type I/II Endoleak During and After EVAR Surgery. Ann. Vasc. Surg. 2025;110:439–446. doi: 10.1016/j.avsg.2024.09.060. [DOI] [PubMed] [Google Scholar]
- 22.Kajiwara K., Yamagami T., Urashima M., Tomiyoshi H., Kakizawa H., Yoshimatsu R., Ishikawa M., Awai K. Embolization for Type 2 Endoleak with Sac Expansion after Endovascular Repair of Abdominal Aortic Aneurysm: Safety and Effectiveness. Springerplus. 2016;5:262. doi: 10.1186/s40064-016-1934-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Steinmetz E., Rubin B.G., Sanchez L.A., Choi E.T., Geraghty P.J., Baty J., Thompson R.W., Flye M.W., Hovsepian D.M., Picus D., et al. Type II Endoleak after Endovascular Abdominal Aortic Aneurysm Repair: A Conservative Approach with Selective Intervention Is Safe and Cost-Effective. J. Vasc. Surg. 2004;39:306–313. doi: 10.1016/j.jvs.2003.10.026. [DOI] [PubMed] [Google Scholar]
- 24.Choi S.Y., Won J.Y., Lee D.Y., Choi D., Shim W.-H., Lee K.-H. Percutaneous Transabdominal Approach for the Treatment of Endoleaks after Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm. Korean J. Radiol. 2010;11:107. doi: 10.3348/kjr.2010.11.1.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Nakai M., Sato H., Sato M., Ikoma A., Sonomura T., Nishimura Y., Okamura Y. Utility of 99mTc–Human Serum Albumin Diethylenetriamine Pentaacetic Acid SPECT for Evaluating Endoleak After Endovascular Abdominal Aortic Aneurysm Repair. Am. J. Roentgenol. 2015;204:189–196. doi: 10.2214/ajr.13.12383. [DOI] [PubMed] [Google Scholar]
- 26.Voigt M.B., Böhner A., Bahaaeldin M., Wagenpfeil J., Dell T., Isaak A., Pieper C.-C., Luetkens J.A., Kupczyk P.A., Meyer C., et al. Periaortic Inflammation after Endoleak Repair: A Risk to Watch. CVIR Endovasc. 2026;9:76. doi: 10.1186/s42155-026-00718-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Van Sickler A.P., Smith A.H., Ellis R.C., Steenberge S.P., Quatromoni J.G., Rowse J.W., Smolock C.J., Caputo F.J., Kirksey L., Lyden S.P. A Novel Technique and Outcomes for Transcaval Endoleak Embolization. Ann. Vasc. Surg. 2023;93:300–307. doi: 10.1016/j.avsg.2023.01.013. [DOI] [PubMed] [Google Scholar]
- 28.Stavropoulos S.W., Kim H., Clark T.W.I., Fairman R.M., Velazquez O., Carpenter J.P. Embolization of Type 2 Endoleaks after Endovascular Repair of Abdominal Aortic Aneurysms with Use of Cyanoacrylate with or without Coils. J. Vasc. Interv. Radiol. 2005;16:857–861. doi: 10.1097/01.rvi.0000156495.66062.62. [DOI] [PubMed] [Google Scholar]
- 29.Buckenham T., McKewen M., Laing A., Roake J., Lewis D., Gordon M.K. Cyanoacrylate Embolization of Endoleaks after Abdominal Aortic Aneurysm Repair. ANZ J. Surg. 2009;79:841–843. doi: 10.1111/j.1445-2197.2009.05113.x. [DOI] [PubMed] [Google Scholar]
- 30.Chao C.P., Fumagalli R.P., Walser E.M., McKinney J.M., Stockland A.H., Falkensammer J., Hakaim A.G., Oldenburg W.A. Percutaneous Protective Coil Occlusion of the Proximal Inferior Mesenteric Artery before N-Butyl Cyanoacrylate Embolization of Type II Endoleaks after Endovascular Repair of Abdominal Aortic Aneurysms. J. Vasc. Interv. Radiol. 2006;17:1827–1833. doi: 10.1097/01.rvi.0000242188.04050.6d. [DOI] [PubMed] [Google Scholar]
- 31.Fujitsuna R., Ueda T., Saito H., Matsumoto T., Shirai S., Sugihara F., Hayashi H., Kumita S. Initial Outcomes of Embolization for Type II Endoleak: Comparison of n-Butyl Cyanoacrylate–Ethiodized Oil Mixture with n-Butyl Cyanoacrylate–Ethiodized Oil–Ethanol Mixture. J. Vasc. Interv. Radiol. 2024;35:1673–1680. doi: 10.1016/j.jvir.2024.07.023. [DOI] [PubMed] [Google Scholar]
- 32.Stavropoulos S.W., Park J., Fairman R., Carpenter J. Type 2 Endoleak Embolization Comparison: Translumbar Embolization versus Modified Transarterial Embolization. J. Vasc. Interv. Radiol. 2009;20:1299–1302. doi: 10.1016/j.jvir.2009.07.003. [DOI] [PubMed] [Google Scholar]
- 33.Ushijima Y., Asayama Y., Nishie A., Ishigami K., Takayama Y., Okamoto D., Fujita N., Morita K., Honda H. Safety and Efficacy of Embolization Using N-Butyl Cyanoacrylate via a Percutaneous Direct Approach for Endoleaks after Abdominal/Thoracic Endovascular Aortic Repair. Interv. Radiol. 2020;5:1–9. doi: 10.22575/interventionalradiology.2018-0018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Wilmot A., Stavropoulos S. Embolization of a Recurrent Type 2 Endoleak Using the Liquid Embolic N-Butyl Cyanoacrylate. Semin. Interv. Radiol. 2007;24:38–42. doi: 10.1055/s-2007-971187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kuziez M.S., Picus D., Sanchez L.A., Zayed M.A. Trans-Luminal Repair of a Ruptured AAA with Type Ia and Type II Endoleaks. J. Surg. Case Rep. 2018;2018:rjy254. doi: 10.1093/jscr/rjy254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Laganà D., Mangini M., Fontana F., Nicotera P., Carrafiello G., Fugazzola C. Percutaneous Treatment of Sac Rupture in Abdominal Aortic Aneurysms Previously Excluded with Endovascular Repair (EVAR) Cardiovasc. Interv. Radiol. 2009;32:178–183. doi: 10.1007/s00270-008-9358-9. [DOI] [PubMed] [Google Scholar]
- 37.Maleux G., Houthoofd S., Buyck P.-J., Bonne L. Type II Endoleak–Related Contained Aortic Rupture Treated by Emergent Translumbar Glue Embolization. J. Vasc. Interv. Radiol. 2025;36:723–726. doi: 10.1016/j.jvir.2024.12.591. [DOI] [PubMed] [Google Scholar]
- 38.Burke C., Mauro M.A. SIR 2003 Film Panel Case 8: Aortocaval Fistula Supplied by a Type II Endoleak. J. Vasc. Interv. Radiol. 2003;14:813–817. doi: 10.1097/01.rvi.0000079996.80153.79. [DOI] [PubMed] [Google Scholar]
- 39.Nakai M., Ikoma A., Loffroy R., Midulla M., Rao P., Kamisako A., Higashino N., Fukuda K., Sonomura T. Transgraft Sac Embolization Combined with Graft Reinforcement for Refractory Mixed-Type Endoleak. Cardiovasc. Interv. Radiol. 2019;42:620–624. doi: 10.1007/s00270-018-2144-4. [DOI] [PubMed] [Google Scholar]
- 40.Chiba E., Hamamoto K., Arakawa M., Uesugi S., Kojima S., Kobayashi R., Ogawa T., Fujii H., Matsuki M., Mori H. Treatment of a Type II Endoleak from an Atypical Mediastinal Collateral Branch Following Total Arch Replacement with Frozen Elephant Trunk. Ann. Vasc. Dis. 2026;19:cr.25-00124. doi: 10.3400/avd.cr.25-00124. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Ahmed Sayed Hamada M., Okada T., Yamaguchi M., Gotake Y., Okada K., Sugimoto K., Murakami T. Atypical Type 2 Endoleak from an Artery Supplying the Psoas Major Muscle Following Endovascular Repair in a Case of Isolated Common Iliac Artery Aneurysm. Interv. Radiol. 2020;5:19–22. doi: 10.22575/interventionalradiology.2019-0004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Claudio R.E., Zuercher H., Vogler J., Zwiebel B. Transgluteal Approach to Hypogastric Artery Aneurysm Type II Endoleak. J. Vasc. Surg. Cas. Innov. Tech. 2023;9:101033. doi: 10.1016/j.jvscit.2022.09.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Onishi M., Onishi Y., Noda T., Yasuo S., Kobiki J., Arai Y., Taniguchi T. Transcatheter Arterial Embolization of a Type 2 Endoleak through the Dorsal Pancreatic Artery after the Hybrid Repair of a Thoracoabdominal Aortic Aneurysm: A Case Report. Radiol. Case Rep. 2023;18:2845–2849. doi: 10.1016/j.radcr.2023.05.047. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Fukunishi T., Nawata S., Nishimaki H., Yamazaki Y., Kinebuchi S., Tomimoto D., Komagamine M., Nawata K. Endovascular Management of Moyamoya Type II Endoleak Utilizing a CO2-Assisted Protection Strategy: A Case Report. J. Endovasc. Ther. 2026:15266028261436277. doi: 10.1177/15266028261436277. [DOI] [PubMed] [Google Scholar]
- 45.Pietura R., Kobak J.E., Kwolek K., Przywara S., Zubilewicz T. Type 2 Endoleak Embolization and Utilization of Non-Contrast-Enhanced Magnetic Resonance Angiography (NCE-MRA) as a Non-Invasive Imaging Follow-up Method. Acta Angiol. 2022;28:63–68. doi: 10.5603/AA.2022.0011. [DOI] [Google Scholar]
- 46.Nakai M., Sato H., Ikoma A., Sonomura T., Sato M. The Use of Technetium-99m–Labeled Human Serum Albumin Diethylenetriamine Pentaacetic Acid Single-Photon Emission CT Scan in the Follow-up of Type II Endoleak Treatment. J. Vasc. Interv. Radiol. 2014;25:405–409. doi: 10.1016/j.jvir.2013.12.004. [DOI] [PubMed] [Google Scholar]
- 47.Shimohira M., Hashizume T., Suzuki Y., Kurosaka K., Muto M., Kitase M., Mizutani M., Shibamoto Y. Triaxial System for Embolization of Type II Endoleak After Endovascular Aneurysm Repair. J. Endovasc. Ther. 2013;20:200–204. doi: 10.1583/1545-1550-20.2.200. [DOI] [PubMed] [Google Scholar]
- 48.Saguchi T., Nakai M., Takara Y., Ikenaga S., Yamada T., Tanaka T., Ishida M., Sugihara E., Saito K. Transarterial Embolization Using the Quintet-Coaxial Catheter System for a Type II Endoleak after Endovascular Aneurysm Repair. Interv. Radiol. 2025;10:e20240011. doi: 10.22575/interventionalradiology.2024-0011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Okada H., Shimohira M., Ikeda S., Ozaki S., Saga T., Taniguchi M., Nakano Y., Takehara Y., Maruchi Y., Narita A., et al. Embolization of a Type 2 Endoleak Using a Micropuncture Introducer Set and a Triple-Coaxial System through the Deep Iliac Circumflex Artery via the Ipsilateral Femoral Artery. Radiol. Case Rep. 2024;19:6220–6224. doi: 10.1016/j.radcr.2024.08.134. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Hongo N., Kiyosue H., Shuto R., Kamei N., Miyamoto S., Tanoue S., Mori H. Double Coaxial Microcatheter Technique for Transarterial Aneurysm Sac Embolization of Type II Endoleaks after Endovascular Abdominal Aortic Repair. J. Vasc. Interv. Radiol. 2014;25:709–716. doi: 10.1016/j.jvir.2014.01.012. [DOI] [PubMed] [Google Scholar]
- 51.Mine T., Ueda T., Yasui D., Mizushima S., Kumita S. Embolization Using Warmed Glue via the Triaxial Microballoon Occlusion System for Various Vascular Disorders. Diagn. Interv. Radiol. 2020;26:241–244. doi: 10.5152/dir.2019.19285. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Katada Y., Kondo S., Takahashi S., Okita Y., Kagoshima A., Rokkaku K., Nozaki M. Direct Percutaneous Puncture Embolization of Type II Endoleaks Using a Coaxial Technique. J. Endovasc. Ther. 2013;20:34–38. doi: 10.1583/12-4065.1. [DOI] [PubMed] [Google Scholar]
- 53.Kamada H., Oguro S., Tannai H., Sakakibara H., Takase K. Super-Selective Embolization Using Flow-Directed Microcatheter and 0.010-Inch Microwire for Type II Endoleak Following Thoracic Endovascular Aortic Repair: A Three-Case Report. Radiol. Case Rep. 2026;21:1–8. doi: 10.1016/j.radcr.2025.09.040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Ogawa Y., Nishimaki H., Fujiwara K., Nathan I.K., Iraha T., Chiba K., Kotoku A., Maruhashi T., Mimura H., Miyairi T. A Novel Technique for the Treatment of Type 2 Endoleak After Endovascular Aortic Repair: Sac Embolization with Balloon Occlusion of the Aorta (SEBOA) Cardiovasc. Interv. Radiol. 2019;42:1488–1493. doi: 10.1007/s00270-019-02299-2. [DOI] [PubMed] [Google Scholar]
- 55.Midulla M., Perini P., Sundareyan R., Lazguet Y., Dehaene A., Goyault G., Martinelli T., Haulon S. Transcatheter Transcaval Embolization of a Type II Endoleak After EVAR Using a Transseptal Needle-Sheath System. Vasc. Endovasc. Surg. 2012;46:410–413. doi: 10.1177/1538574412448683. [DOI] [PubMed] [Google Scholar]
- 56.Ogawa Y., Hamaguchi S., Nishimaki H., Kon Y., Chiba K., Sakurai Y., Murakami K., Arai Y., Miyairi T., Nakajima Y. Embolization by Direct Puncture with a Transpedicular Approach Using an Isocenter Puncture (ISOP) Method in a Patient with a Type II Endoleak After Endovascular Aortic Repair (EVAR) Cardiovasc. Interv. Radiol. 2015;38:731–735. doi: 10.1007/s00270-015-1065-8. [DOI] [PubMed] [Google Scholar]
- 57.Churchill D., Motaganahalli R., LaRoche T., Ramkaransingh J. A Novel Approach for Treating Type II Endoleaks Utilizing Contrast-Enhanced Ultrasound. J. Vasc. Surg. Cas. Innov. Tech. 2021;7:581–585. doi: 10.1016/j.jvscit.2021.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Forester N.D., Parry D., Kessel D., Robertson I., Patel J., Scott D.J.A. Ischaemic Sciatic Neuropathy: An Important Complication of Embolisation of a Type II Endoleak. Eur. J. Vasc. Endovasc. Surg. 2002;24:462–463. doi: 10.1053/ejvs.2002.1718. [DOI] [PubMed] [Google Scholar]
- 59.Sanz-Sánchez J., Poretti D., Poletto G., Civilini E. Paraplegia Due to Spinal Cord Ischemia after Endovascular Treatment of a Type II Endoleak. Ann. Vasc. Surg. 2019;61:472.e1–472.e3. doi: 10.1016/j.avsg.2019.05.054. [DOI] [PubMed] [Google Scholar]
- 60.Gabel J., Teruya T., Bianchi C., Kiang S.C., Patel S., Abou-Zamzam A.M. Ischemic Colitis after Translumbar N-Butyl Cyanoacrylate Injection for Treatment of Endoleak. J. Vasc. Surg. Cas. Innov. Tech. 2018;4:238–239. doi: 10.1016/j.jvscit.2018.04.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Saiga A., Koizumi J., Ueda H., Yokota H., Kubota Y., Wada T., Akutsu A., Higuchi A., Umeda K., Yamauchi S., et al. Ischemic Lumbar Plexopathy After Transarterial Embolization of Type II Endoleak Using N-Butyl-2-Cyanoacrylate. Cardiovasc. Interv. Radiol. 2022;45:536–538. doi: 10.1007/s00270-021-03019-5. [DOI] [PubMed] [Google Scholar]
- 62.Metias M.M., Kayssi A., Lindsay T.F., Rajan D.K. Management of Acute Limb Ischemia after Glue Embolization of Endoleak Following Endovascular Abdominal Aortic Aneurysm Repair. J. Vasc. Surg. Cases. 2015;1:217–220. doi: 10.1016/j.jvsc.2015.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Lanza E., Poretti D., Tramarin M., Pedicini V., Balzarini L. Colonic Ischemia, Perforation, and Colectomy after a Complicated Endovascular Embolization for Type II Endoleak with the Use of Cyanoacrylate Glue. J. Vasc. Interv. Radiol. 2014;25:1482–1484. doi: 10.1016/j.jvir.2014.05.018. [DOI] [PubMed] [Google Scholar]
- 64.Ito T., Kurimoto Y., Kawaharada N., Koyanagi T., Maeda T., Yanase Y., Nakazawa J., Hirokawa N., Higami T. Ischemic Colitis Following Transarterial Embolization for Type 2 Endoleak of EVAR: Report of a Case. Ann. Vasc. Dis. 2012;5:92–95. doi: 10.3400/avd.cr.11.00081. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Bailey M.A., McPherson S.J., Troxler M.A., Peach A.H.S., Patel J.V., Scott D.J.A. Ischemic Skin Ulceration Complicating Glue Embolization of Type II Endoleak after Endovascular Aneurysm Repair. J. Vasc. Interv. Radiol. 2011;22:163–167. doi: 10.1016/j.jvir.2010.10.018. [DOI] [PubMed] [Google Scholar]
- 66.Ueda T., Fujitsuna R., Saito H., Iwasaki M., Hayashi H., Kumita S. Acute Lower Limb Ischemia from Stent-Graft Limb Compression after n-Butyl Cyanoacrylate–Ethiodized Oil–Ethanol Mixture Sac Embolization for a Type II Endoleak. J. Vasc. Interv. Radiol. 2026;37:107858. doi: 10.1016/j.jvir.2025.09.029. [DOI] [PubMed] [Google Scholar]
- 67.Maleux G., Mufty H. Limb Graft Occlusion after Translumbar Glue Embolization of a Type II Endoleak. J. Vasc. Interv. Radiol. 2026;37:107931. doi: 10.1016/j.jvir.2025.107931. [DOI] [PubMed] [Google Scholar]
- 68.Ni W., Leong S., Chng J.K., Tay K.H. Extrinsic Compression of the Ovation Stent-Graft Following Glue Embolization for Type II Endoleak: An Unusual Complication. J. Endovasc. Ther. 2018;25:252–254. doi: 10.1177/1526602818757013. [DOI] [PubMed] [Google Scholar]
- 69.Robinson N., Tallarita T., Beckermann J., Nijhawan V., McBride J., Saran N., Carmody T., Wildenberg J. Infected Stent Graft and Severe Aortitis after Transcaval Glue Embolization of Type II Endoleak: A Case Report. AME Case Rep. 2024;8:70. doi: 10.21037/acr-23-148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Balézeaux Q., Leroux A., Krug B., Rondelet B., Belhaj A. Early and Severe Aortic Endograft Infection after Percutaneous Coil Embolization of Type 2 Endoleak: A Case Report. Int. J. Surg. Case Rep. 2024;122:110140. doi: 10.1016/j.ijscr.2024.110140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Li B., Tan K.T., MacDonald M.E., Byrne J. Aortic Graft Infection with Enteric Organism after Embolization of Late Type II Endoleak. J. Vasc. Surg. Cas. Innov. Tech. 2019;5:61–64. doi: 10.1016/j.jvscit.2018.10.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Wong G.R., Yu H., Isaacson A.J. Comparison of Cost and Efficacy of Trufill® vs Histoacryl® N-Butyl Cyanoacrylate for Translumbar Type 2 Endoleak Embolization. Vasc. Endovasc. Surg. 2021;55:152–157. doi: 10.1177/1538574420973821. [DOI] [PubMed] [Google Scholar]
- 73.Okada K., Shimura S., Koizumi J., Kotani S., Odagiri S., Sekiguchi T., Ozawa K., Yamamoto A., Kishinami G., Naiki T., et al. Efficacy of Preemptive Embolization of Sac Branches During Endovascular Aneurysm Repair Using N-Butyl-2-Cyanoacrylate. Tokai J. Exp. Clin. Med. 2024;49:43–47. [PubMed] [Google Scholar]
- 74.Nakai M., Ikoma A., Sato M., Sato H., Nishimura Y., Okamura Y. Prophylactic Intraoperative Embolization of Abdominal Aortic Aneurysm Sacs Using N -Butyl Cyanoacrylate/Lipiodol/Ethanol Mixture with Proximal Neck Aortic Balloon Occlusion during Endovascular Abdominal Aortic Repair. J. Vasc. Interv. Radiol. 2016;27:954–960. doi: 10.1016/j.jvir.2016.03.037. [DOI] [PubMed] [Google Scholar]
- 75.Miura S., Kurimoto Y., Maruyama R., Masuda T., Yanase Y., Iba Y., Nojima M., Yamada A. Endovascular Aortic Aneurysm Repair without Type 2 Endoleak Using Concomitant N-Butyl-2-Cyanoacrylate Injection into the Abdominal Aortic Aneurysm Sac. Ann. Vasc. Surg. 2020;66:110–119. doi: 10.1016/j.avsg.2019.12.006. [DOI] [PubMed] [Google Scholar]
- 76.Miura S., Kurimoto Y., Maruyama R., Nojima M., Sasaki K., Masuda T., Nishioka N., Naraoka S. Injection of N-Butyl-2-Cyanoacrylate into the Abdominal Aortic Aneurysm Sac during Endovascular Aortic Repair to Prevent Type II Endoleaks Caused by Lumbar Arteries. J. Vasc. Interv. Radiol. 2024;35:676–686. doi: 10.1016/j.jvir.2023.12.573. [DOI] [PubMed] [Google Scholar]
- 77.Ultee K.H.J., Büttner S., Huurman R., Bastos Gonçalves F., Hoeks S.E., Bramer W.M., Schermerhorn M.L., Verhagen H.J.M. Editor’s Choice—Systematic Review and Meta-Analysis of the Outcome of Treatment for Type II Endoleak Following Endovascular Aneurysm Repair. Eur. J. Vasc. Endovasc. Surg. 2018;56:794–807. doi: 10.1016/j.ejvs.2018.06.009. [DOI] [PubMed] [Google Scholar]
- 78.Nana P., Spanos K., Heidemann F., Panuccio G., Kouvelos G., Rohlffs F., Giannoukas A., Kölbel T. Systematic Review on Transcaval Embolization for Type II Endoleak after Endovascular Aortic Aneurysm Repair. J. Vasc. Surg. 2022;76:282–291.e2. doi: 10.1016/j.jvs.2022.02.032. [DOI] [PubMed] [Google Scholar]
- 79.Yu H.Y.H., Lindström D., Wanhainen A., Tegler G., Asciutto G., Mani K. An Updated Systematic Review and Meta-Analysis of Pre-Emptive Aortic Side Branch Embolization to Prevent Type II Endoleaks after Endovascular Aneurysm Repair. J. Vasc. Surg. 2023;77:1815–1821. doi: 10.1016/j.jvs.2022.11.042. [DOI] [PubMed] [Google Scholar]
- 80.Lopez Espada C., Behrendt C.-A., Mani K., D’Oria M., Lattman T., Khashram M., Altreuther M., Cohnert T.U., Pherwani A., Budtz-Lilly J., et al. Editor’s Choice—The VASCUNExplanT Project: An International Study Assessing Open Surgical Conversion of Failed Non-Infected Endovascular Aortic Aneurysm Repair. Eur. J. Vasc. Endovasc. Surg. 2023;66:653–660. doi: 10.1016/j.ejvs.2023.07.029. [DOI] [PubMed] [Google Scholar]
- 81.Koudounas G., Bontinis V., Giannopoulos S., Bontinis A., Tassiopoulos A., Karkos C.D. Rupture after Previous Endovascular Abdominal Aortic Aneurysm Repair: A Meta-Analysis and Meta-Regression Analysis of Factors Influencing Perioperative Mortality. J. Vasc. Surg. 2025;82:1097–1110.e3. doi: 10.1016/j.jvs.2025.02.048. [DOI] [PubMed] [Google Scholar]
- 82.Takasawa C., Seiji K., Matsunaga K., Matsuhashi T., Ohta M., Shida S., Takase K., Takahashi S. Properties of N-Butyl Cyanoacrylate–Iodized Oil Mixtures for Arterial Embolization: In Vitro and In Vivo Experiments. J. Vasc. Interv. Radiol. 2012;23:1215–1221.e1. doi: 10.1016/j.jvir.2012.06.022. [DOI] [PubMed] [Google Scholar]
- 83.Nakai M., Saguchi T., Yunaiyama D., Takara Y., Tanaka T., Okada Y., Saito K. Development and Experimental Study of a Polytetrafluoroethylene-Tipped Microcatheter Poorly Adhesive to n-Butyl-2-Cyanoacrylate. J. Endovasc. Ther. 2025;32:1745–1750. doi: 10.1177/15266028231208652. [DOI] [PubMed] [Google Scholar]
- 84.Loffroy R. Glubran2®, Histoacryl® or Trufill®: Which Cyanoacrylate Glue for Endovascular Use? Diagn. Interv. Imaging. 2016;97:119. doi: 10.1016/j.diii.2015.04.011. [DOI] [PubMed] [Google Scholar]
- 85.Tanaka F., Kawai N., Sato M., Minamiguchi H., Nakai M., Nakata K., Sanda H., Sonomura T., Matuzaki I., Murata S. Effect of Transcatheter Arterial Embolization with a Mixture of N-Butyl Cyanoacrylate, Lipiodol, and Ethanol on the Vascular Wall: Macroscopic and Microscopic Studies. Jpn. J. Radiol. 2015;33:404–409. doi: 10.1007/s11604-015-0432-3. [DOI] [PubMed] [Google Scholar]
- 86.Mine T., Yasui D., Saito H., Ueda T., Yokoyama T., Ikeda S., Mizushima S., Happoh S., Kumita S. Effects of Temperature Alteration on Viscosity, Polymerization, and in-Vivo Arterial Distribution of N-Butyl Cyanoacrylate-Iodized Oil Mixtures. Jpn. J. Radiol. 2021;39:1111–1118. doi: 10.1007/s11604-021-01143-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Gandini R., Chiocchi M., Loreni G., Del Giudice C., Morosetti D., Chiaravalloti A., Simonetti G. Treatment of Type II Endoleak After Endovascular Aneurysm Repair: The Role of Selective vs. Nonselective Transcaval Embolization. J. Endovasc. Ther. 2014;21:714–722. doi: 10.1583/14-4571mr.1. [DOI] [PubMed] [Google Scholar]
- 88.Sarac T.P., Gibbons C., Vargas L., Liu J., Srivastava S., Bena J., Mastracci T., Kashyap V.S., Clair D. Long-Term Follow-up of Type II Endoleak Embolization Reveals the Need for Close Surveillance. J. Vasc. Surg. 2012;55:33–40. doi: 10.1016/j.jvs.2011.07.092. [DOI] [PubMed] [Google Scholar]
- 89.Horinouchi H., Okada T., Yamaguchi M., Maruyama K., Sasaki K., Gentsu T., Ueshima E., Sofue K., Kawasaki R., Nomura Y., et al. Mid-Term Outcomes and Predictors of Transarterial Embolization for Type II Endoleak After Endovascular Abdominal Aortic Aneurysm Repair. Cardiovasc. Interv. Radiol. 2020;43:696–705. doi: 10.1007/s00270-020-02436-2. [DOI] [PubMed] [Google Scholar]
- 90.Massis K., Carson W.G., Rozas A., Patel V., Zwiebel B. Treatment of Type II Endoleaks with Ethylene-Vinyl-Alcohol Copolymer (Onyx) Vasc. Endovasc. Surg. 2012;46:251–257. doi: 10.1177/1538574412442401. [DOI] [PubMed] [Google Scholar]
- 91.Jamieson R.W., Bachoo P., Tambyraja A.L. Evidence for Ethylene-Vinyl-Alcohol-Copolymer Liquid Embolic Agent as a Monotherapy in Treatment of Endoleaks. Eur. J. Vasc. Endovasc. Surg. 2016;51:810–814. doi: 10.1016/j.ejvs.2016.02.015. [DOI] [PubMed] [Google Scholar]
- 92.Sun Y., Cai H.-B., Yang D., Li W.-Y., Zhao W., Hu J.-H., Li M., Peng M.-S., Yuan F., Qing K.-X. Volumetric Analysis of Effectiveness of Embolization for Preventing Type II Endoleaks Following Endovascular Aortic Aneurysm Repair. J. Vasc. Surg. 2023;77:752–759.e2. doi: 10.1016/j.jvs.2022.10.033. [DOI] [PubMed] [Google Scholar]
- 93.Chen Y., Zhang L., Liu Z., Bi J., Niu F., Zhang X., Lu Q., Dai X. Fibrin Glue Sac Filling for Preventing Type II Endoleak, Short-Term Outcomes of a Prospective Randomized Controlled Trial. J. Endovasc. Ther. 2024;31:1005–1012. doi: 10.1177/15266028231159245. [DOI] [PubMed] [Google Scholar]
- 94.Shukuzawa K., Ohki T., Maeda K., Kanaoka Y. Risk Factors and Treatment Outcomes for Stent Graft Infection after Endovascular Aortic Aneurysm Repair. J. Vasc. Surg. 2019;70:181–192. doi: 10.1016/j.jvs.2018.10.062. [DOI] [PubMed] [Google Scholar]
- 95.Yang R.Y., Tan K.T., Beecroft J.R., Rajan D.K., Jaskolka J.D. Direct Sac Puncture versus Transarterial Embolization of Type II Endoleaks: An Evaluation and Comparison of Outcomes. Vascular. 2017;25:227–233. doi: 10.1177/1708538116663992. [DOI] [PubMed] [Google Scholar]
- 96.Yu H., Desai H., Isaacson A.J., Dixon R.G., Farber M.A., Burke C.T. Comparison of Type II Endoleak Embolizations: Embolization of Endoleak Nidus Only versus Embolization of Endoleak Nidus and Branch Vessels. J. Vasc. Interv. Radiol. 2017;28:176–184. doi: 10.1016/j.jvir.2016.10.002. [DOI] [PubMed] [Google Scholar]
- 97.Haulon S., Tyazi A., Willoteaux S., Koussa M., Lions C., Beregi J.-P. Embolization of Type II Endoleaks after Aortic Stent-Graft Implantation: Technique and Immediate Results. J. Vasc. Surg. 2001;34:600–605. doi: 10.1067/mva.2001.117888. [DOI] [PubMed] [Google Scholar]
- 98.Zener R., Oreopoulos G., Beecroft R., Rajan D.K., Jaskolka J., Tan K.T. Transabdominal Direct Sac Puncture Embolization of Type II Endoleaks after Endovascular Abdominal Aortic Aneurysm Repair. J. Vasc. Interv. Radiol. 2018;29:1167–1173. doi: 10.1016/j.jvir.2018.04.002. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data are available upon request.
